Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long‐term extension study: A descriptive subgroup analysis in women with anemia at baseline

Abstract

AbstractObjectiveTo investigate the effects of 52 weeks of treatment with relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) on symptoms of uterine fibroids (UF) and quality of life (QoL) in women with heavy menstrual bleeding associated with UF and anemia (hemoglobin ≤10.5 g/dL) at baseline.MethodsThis post hoc analysis included women from the LIBERTY long‐term extension study with anemia (hemoglobin concentration ≤10.5 g/dL) at pivotal study baseline and documented hemoglobin values at week 52 (anemia‐evaluable population). Treatment responders: women achieving a menstrual blood loss volume of <80 mL and a ≥50% reduction over the last 35 days of treatment. Anemia responders were women achieving a hemoglobin increase of >2 g/dL from baseline to week 52. Least squares (LS) mean changes from baseline in uterine fibroid symptom (UFS)‐QoL symptom severity, fatigue, and health‐related QoL total (HR‐QoL) and (sub)scale scores were calculated.ResultsIn total, 115 women were included in the anemia‐evaluable population. Of 39 anemia‐evaluable women who received continuous treatment with relugolix combination therapy for 52 weeks, 34 (87.2%) met treatment responder criteria and 23 (59.0%) were anemia responders. LS mean hemoglobin concentration increased by 29.4% at week 52. LS mean UFS‐QoL symptom severity and fatigue scores decreased by 38.5 and 31.9 points, respectively, and HR‐QoL total score increased by 41.6 points.ConclusionIn women with UF and a high disease burden due to anemia, relugolix combination therapy substantially improved hemoglobin levels, decreased distress due to symptoms, especially fatigue, over 52 weeks.